16Oct 2019

A COMPARATIVE STUDY OF TRANSDERMAL BUPRENORPHINE WITH TRANSDERMAL FENTANYL FOR POSTOPERATIVE ANALGESIA IN PATIENTS UNDERGOING POSTERIOR STABILIZATION OF LUMBAR SPINE.

  • Associate Professor, Dept. of Anaesthesiology, Father Muller Medical College, Mangalore-575002 India.
  • Senior Resident, Dept. of Anaesthesiology, St. Johns Medical College and Hospital, Bangalore-560034 India.
Crossref Cited-by Linking logo
  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Background and Objectives: Posterior stabilization of lumbar spine is associated with high degree of postoperative pain and hence, effective analgesia is a priority in this patient population as inadequate management of acute pain in the long run can result in chronic pain. Newer modalities of analgesia that are safe, non-invasive and user friendly are constantly being investigated. One such example of an analgesic is the transdermal system of opioid drugs. The pharmacological and clinical profiles of buprenorphine and fentanyl make them suitable for transdermal use. We conducted this study to find out which among the two is more effective for postoperative analgesia and which drug patch has a better side-effect profile. Methods: Sixty patients who gave their informed consent, aged between 18-60 years undergoing elective posterior stabilization of lumbar spine, were divided into two groups of 30 each and were assigned to receive either a fentanyl patch (25 μg/hour) or a buprenorphine patch (10μg/hr). Vitals were closely monitored in the postoperative period and if the VAS scores were >4, rescue analgesia was administered. Results: VAS scores were significantly lower in the group that received fentanyl patch. Those who received the buprenorphine patch experienced more frequent breakthrough pain and thus needed more rescue analgesia. However, fentanyl group experienced more nausea. Conclusion: The study hence concluded that for postoperative analgesia, transdermal fentanyl holds promise. More studies on a larger scale need to be conducted to consolidate this finding.

  1. Voscopoulos C, Lema M. When does acute pain become chronic? Br J Anaesth. 2010;105:69?85.
  2. Katz J, Jackson M, Kavanagh BP, Sandler a N. Acute pain after thoracic surgery predicts long-term post-thoracotomy pain. Clin J Pain. 1996;12(1):50?5.
  3. Andresen T, Staahl C, Oksche A, Mansikka H, Arendt-Nielsen L, Drewes AM. Effect of transdermal opioids in experimentally induced superficial, deep and hyperalgesic pain. Br J Pharmacol. 2011;164(3):934?45.
  4. Kapil RP, Cipriano A, Friedman K, Michels G, Shet MS, Colucci S V., et al. Once-weekly transdermal buprenorphine application results in sustained and consistent steady-state plasma levels. J Pain Symptom Manage. 2013;46(1):65?75.
  5. Budd K. Buprenorphine and the transdermal system: the ideal match in pain management. Int J Clin Pract Suppl. 2003;(February):9?14.
  6. Nelson L, Schwaner R. Transdermal fentanyl: pharmacology and toxicology. J Med Toxicol. 2009;5(4):230?41.
  7. Dancik Y, Anissimov YG, Jepps OG, Roberts MS. Convective transport of highly plasma protein bound drugs facilitates direct penetration into deep tissues after topical application. Br J Clin Pharmacol. 2012;73(4):564?78.
  8. Lef?vre G, Sędek G, Jhee SS, Leibowitz MT, Huang H-L, Enz A, et al. Pharmacokinetics and Pharmacodynamics of the Novel Daily Rivastigmine Transdermal Patch Compared With Twice-daily Capsules in Alzheimer?s Disease Patients. Clin Pharmacol Ther. 2008;83(1):106?14.
  9. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2009;26(11):1261?8.
  10. World Health Organization. WHO List of Essential Medicines (EML) 20th edition. 2017;(20th Edition):62.
  11. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, et al. DrugBank 3.0: A comprehensive resource for ?Omics? research on drugs. Nucleic Acids Res. 2011;39(SUPPL. 1).
  12. Labroo RB, Paine MF, Thummel KE, Kharasch ED. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: Implications for interindividual variability in disposition, efficacy, and drug interactions. Drug Metab Dispos. 1997;25(9):1072?80.
  13. Hair PI, Keating GM, McKeage K. Transdermal matrix fentanyl membrane patch (Matrifen??): In severe cancer-related chronic pain. Drugs. 2008;68(14):2001?9.
  14. Ashburn MA, Ogden LL, Zhang J, Love G, Basta S V. The pharmacokinetics of transdermal fentanyl delivered with and without controlled heat. J Pain. 2003;4(6):291?7.
  15. Heel RC, Brogden RN, Speight TM, Avery GS. Buprenorphine: A Review of its Pharmacological Properties and Therapeutic Efficacy. Drugs. 1979;17(2):81?110.
  16. Sittl R, Griessinger N, Likar R. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: A multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther. 2003;25(1):150?68.
  17. Dahan A, Yassen A, Romberg R, Sarton E, Teppema L, Olofsen E, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth. 2006;96(5):627?32.
  18. Cone EJ, Gorodetzky CW, Yousefnejad D, Buchwald WF, Johnson RE. The metabolism and excretion of buprenorphine in humans. Drug Metab Dispos. 1984;12(5):577?81.
  19. Andresen T, Upton RN, Foster DJR, Christrup LL, Arendt-Nielsen L, Drewes AM. Pharmacokinetic/Pharmacodynamic Relationships of Transdermal Buprenorphine and Fentanyl in Experimental Human Pain Models. Basic Clin Pharmacol Toxicol. 2011;108(4):274?84.
  20. Kilbride M, Morse M, Senagore A. Transdermal fentanyl improves management of postoperative hemorrhoidectomy pain. Dis Colon Rectum. 1994;37(11):1070?2.
  21. Lehmann LJ, DeSio JM, Radvany T, Bikhazi GB. Transdermal fentanyl in postoperative pain. Reg Anesth. 1997;22(1):24?8.
  22. Evans HC, Easthope SE. Transdermal buprenorphine. Drugs. 2003;63(19):1999?2010.
  23. Dahan A, Yassen A, Bijl H, Romberg R, Sarton E, Teppema L, et al. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth. 2005;94(6):825?34.
  24. Sittl R, Likar R, Nautrup BP. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: Results of a retrospective cohort study. Clin Ther. 2005;27(2):225?37.
  25. Griessinger N, Sittl R, Likar R. Transdermal buprenorphine in clinical practice--a post-marketing surveillance study in 13,179 patients. Curr Med Res Opin. 2005;21(8):1147?56.
  26. Sittl R, Nuijten M, Poulsen Nautrup B. Patterns of Dosage changes with transdermal buprenorphine and transdermal fentanyl for the treatment of noncancer and cancer pain: A retrospective data analysis in Germany. Clin Ther. 2006;28(8):1144?54.
  27. Minville V, Lubrano V, Bounes V, Pianezza A, Rabinowitz A, Gris C, et al. Postoperative analgesia after total hip arthroplasty: patient-controlled analgesia versus transdermal fentanyl patch. J Clin Anesth. 2008;20(4):280?3.
  28. Mercadante S, Casuccio A, Tirelli W, Giarratano A. Equipotent doses to switch from high doses of opioids to transdermal buprenorphine. Support Care Cancer. 2009;17(6):715?8.
  29. Wirz S, Wittmann M, Schenk M, Schroeck A, Schaefer N, Mueller M, et al. Gastrointestinal symptoms under opioid therapy: A prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine. Eur J Pain. 2009;13(7):737?43.
  30. Plosker GL, Lyseng-Williamson KA. Buprenorphine 5, 10 and 20 mcg/h transdermal patch: A guide to its use in chronic non-malignant pain. CNS Drugs. 2012;26(4):367?73.
  31. Wolff RF, Reid K, Di Nisio M, Aune D, Truyers C, Hernandez A V, et al. Systematic review of adverse events of buprenorphine patch versus fentanyl patch in patients with chronic moderate-to-severe pain. Pain Manag. 2012;2(4):351?62.
  32. Setti T, Sanfilippo F, Leykin Y. Transdermal buprenorphine for postoperative pain control in gynecological surgery: a prospective randomized study. Curr Med Res Opin. 2012;28(10):1597?608.
  33. Lee BH, Park J-O, Suk K-S, Kim T-H, Lee H-M, Park M-S, et al. Pre-emptive and multi-modal perioperative pain management may improve quality of life in patients undergoing spinal surgery. Pain Physician. 2013;16(3):217?26.
  34. Canneti A, Luzi M, Di Marco P, Cannata F, Pasqualitto F, Spinoglio A, et al. Safety and efficacy of transdermal buprenorphine and transdermal fentanyl in the treatment of neuropathic pain in AIDS patients. Minerva Anestesiol. 2013;79(8):871?83.
  35. Sathitkarnmanee T, Tribuddharat S N et al. Transdermal fentanyl patch for postoperative analgesia in total knee arthroplasty: A randomized double-blind controlled trial. J Pain Res. 2014;7:449?54.
  36. Arshad Z, Prakash R, Gautam S, Kumar S. Comparison between transdermal buprenorphine and transdermal fentanyl for postoperative pain relief after major abdominal surgeries. J Clin Diagnostic Res. 2015;9(12):1?4.
  37. Matsumoto S, Matsumoto K, Iida H. Transdermal fentanyl patch improves post-operative pain relief and promotes early functional recovery in patients undergoing primary total knee arthroplasty: a prospective, randomised, controlled trial. Arch Orthop Trauma Surg. 2015;135(9):1291?7.
  38. Kumar S, Chaudhary AK, Singh PK, Verma R, Chandra G, Bhatia VK, et al. Transdermal buprenorphine patches for postoperative pain control in abdominal surgery. J Clin Diagnostic Res. 2016;10(6):UC05-UC08.
  39. Conaghan PG, O?Brien CM, Wilson M, Schofield JP. Transdermal buprenorphine plus oral paracetamol vs an oral codeine-paracetamol combination for osteoarthritis of hip and/or knee: A randomised trial. Osteoarthr Cartil. 2011;19(8):930?8.
  40. Pergolizzi J V, Raffa RB, Marcum Z, Colucci S, Ripa SR. Safety of buprenorphine transdermal system in the management of pain in older adults. Postgrad Med. 2017;129(1):92?101.
  41. Marino PL, Sutin KM. The ICU Book.Sedation in ICU.Table 49.3.

[Kishan Shetty MD and Seena Marene Solomon MD. (2019); A COMPARATIVE STUDY OF TRANSDERMAL BUPRENORPHINE WITH TRANSDERMAL FENTANYL FOR POSTOPERATIVE ANALGESIA IN PATIENTS UNDERGOING POSTERIOR STABILIZATION OF LUMBAR SPINE. Int. J. of Adv. Res. 7 (Oct). 327-349] (ISSN 2320-5407). www.journalijar.com

DR. SEENA MARENE SOLOMON

DOI:

Article DOI: 10.21474/IJAR01/9836      
DOI URL: http://dx.doi.org/10.21474/IJAR01/9836

Download Full Paper

Download PDF No. of Downloads: 143 | No. of Views: 408